5 years ago

Pneumagen Secures £4 Million for COVID-19 Treatment Development

  • Pneumagen, a UK-based company developing treatments for infectious diseases, has raised £4 million in funding led by Thairm Bio with participation from the Scottish Investment Bank

  • The funds will be used to advance the clinical development of Neumifil for the prevention and treatment of COVID-19

  • Neumifil is a Carbohydrate Binding Modules (mCBMs) generated using Pneumagen's proprietary GlycoTarge™ platform

  • It is being developed for the treatment of respiratory tract infections caused by Influenza Virus, Respiratory Syncytial Virus, and coronaviruses including SARS-CoV-2.

      • ProblemHealthcare

      "Infectious diseases like COVID-19 are a major global health threat, and existing treatments are often ineffective or have serious side effects. "

      Solution

      "Pneumagen is developing a new drug called Neumifil that targets the human glycome to treat infectious diseases. Neumifil is a Carbohydrate Binding Modules (mCBMs) generated using its proprietary GlycoTarge™ platform. This drug is designed to be effective against a wide range of respiratory tract infections, including influenza, RSV, and coronaviruses."

      Covered on